+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Personalized Cancer Vaccine Market, Clinical Trials & Future Outlook 2026

  • ID: 4848781
  • Report
  • Region: Global
  • 170 Pages
  • Kuick Research
1 of 4

FEATURED COMPANIES

  • Advaxis Inc.
  • Avax Technologies
  • Celldex
  • Genetech
  • Gristone Oncology
  • Kite Pharma
  • MORE

Report Highlights:

  • Personalized Cancer Vaccine Mechanism of Action
  • Biomarkers Importance  In Personalized Vaccines
  • Ongoing Clinical Trials on Personalized Cancer Vaccine
  • Developmental Cost Analysis of a Personalized Cancer Vaccine
  • Immune Checkpoint Biomarkers Preventing Tumor Growth
  • Advancements in the Personalized Cancer Vaccine
  • Current Market Trends & Advancements in the Personalized Cancer Vaccine Segment

The treatment of cancer through the aspect of using a vaccine that has been personalized according to the requirement with an approach that the therapy will provide no harm in the future is innovative yet challenging. The concept of personalized vaccine is recognized as a paradigm shift for the way the cancer is treated and the way cancer is seen in the future. Although many other therapies are available in the present for the treatment of cancer majority of the therapies come with their own drawbacks and undesirable outcomes.

Personalized vaccine allows us to take a giant step towards the treatment of cancer as in each person’s cancer the case is different and the therapy is customized according to the individual cancer scenario. Personalized vaccines when compared with the already existing therapies, has accomplished great success, with respect to the wide utilization of the treatment in different cancer types. The idea of fitting every cancer patient to the limited drugs has come to an end with the participation of this novel therapeutics into the active field of oncology.

The therapy approaches the development of a neoantigen vaccine that stimulates the immune system to attack the malignant cells in a unique way. Currently, the personalized cancer vaccine of the immunotherapy segment is undergoing rapid advancements and improvements with the help of highly skilled researchers at the top universities and laboratories all around the world. Recent research published by some leading science journals reported excellent and emerging outcomes about the cancer vaccines. The current study about the segment is limited to lab animals, but once the testing is over, it will be tested in humans for the first time.

A number of clinical trials regarding investigational therapy are currently mid-way of becoming the future of cancer therapies. In the current scenario, the USA and Europe are leading the race of having the major market players. Increasing adoption of healthcare and advancements in genome sequencing techniques are the major contributors to the huge market share in the region.

The research and development of personalized vaccine is supported by both private as well as public sectors by rising their investments in the personalized cancer vaccine segment. The advantage of increasing fundings can provide a valuable option to the patients as well as the research sector. CureVac, Kite Pharma, Alphabet, Modema & Merck are some of the major investors in the personalized cancer vaccine segment. The development made by the researchers plays an important role in setting up newly available treatments as they will contribute significantly to the cancer treatment and driving the market size by many folds.

The idea behind the development of personalized vaccines is an exception from all the cancer treatments that we all are dependent on. As per report findings, personalized vaccine is successful in showing tremendous progress in the research area and in the future it will be a promising approach for treating certain tumors and other inflammatory diseases related to cancer. In the upcoming years, the increasing number of cancer patients is expected to increase the market size and revolutionize the entire market for cancer therapies available.

This report on the personalized cancer vaccine market provides a comprehensive insight into the current status of the segment with special emphasis on the clinical innovations governing the market. The report also highlights the clinical relevance of personalized cancer vaccine, trends and recent advances that will impact the growth of the market. Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2026.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advaxis Inc.
  • Avax Technologies
  • Celldex
  • Genetech
  • Gristone Oncology
  • Kite Pharma
  • MORE

1. Personalized Cancer Vaccine: Revolutionizing the Immunotherapeutics of the Future
1.1 The Approach Towards Cancer Vaccine Strategy
1.2 Cancer Vaccines - Current Clinical Trials Scenario

2. Personalized Cancer Vaccine Mechanism of Action
2.1 Entities Involved in Personalized Cancer Vaccine & Their Respective Contributions
2.1.1 Tumor Neo - Antigens
2.1.2 Human Leukocyte Antigen
2.2 General Working of Personalized Cancer Vaccine
2.3 Genetic Polymorphism Leading to Pharmacogenomics
2.4 Cancer Pharmacogenomics Observing Somatic Mutations

3. Biomarkers Importance  In Personalized Vaccines
3.1 Pharmacogenomic Biomarkers
3.2 Prognostic & Predictive Biomarkers

4. Ongoing Clinical Trials on Personalized Medicines
4.1 NEO-PV-01 Showing Glimmers of Success against Melanoma
4.2 Personalized Vaccine: An Evolving Biological Discovery for Pancreatic Cancer
4.3 Precision Cancer Vaccine against Metastatic Colorectal Cancer
4.4 First-in-Human Trial of Personalized Vaccine for Glioblastoma (Brain Tumor)
4.5 TG4001 in Combination with Avelumab against HPV Cancers

5. Immune Checkpoint Biomarkers Preventing Tumor Growth
5.1 Emerging Biomarkers for CTLA4
5.2 PD-1/PD-L1

6. Personalized Cancer Vaccine: Manufacturing Process & Cost Analysis Study
6.1 Pre - Manufacturing Cost Analysis
6.2 Segmented Cost Analysis of Personalized Cancer Vaccine
6.2.1 Capital Cost
6.2.2 Cost of Raw Materials
6.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
6.2.4 Factory & Administrative Overheads
6.2.5 Filling & Packaging
6.3 Per Patient Cost

7. Current Market Trends & Advancements in the Personalized Cancer Vaccine Segment
7.1 Researchers Improving the Outcome of Future Personalized Cancer Vaccine
7.2 Increasing Investments
7.3 Personalized Cancer Vaccine Development using mRNA
7.4 Personalized Cancer Vaccine Market Receiving Collaborations & Ventures Ensure Stable Funding
7.5 DNA Sequencing Technology Development  Driving the Personalized Cancer Vaccine Market

8. Global - Personalized Cancer Vaccine Market Segmentation by Cancer Type
8.1 Personalized Cancer Vaccine  Breakthrough against Melanoma
8.2 Lung Cancer Prevention using Personalized Vaccines
8.3 Personalized Cancer Vaccines towards Eliminating Breast Cancer
8.4 Colorectal Cancer Eradication by Personalized Cancer Vaccines
8.5 Scope of Leukemia Treatment using Personalized Cancer Vaccines
8.6 Prostate Cancer Eradication using Personalized Cancer vaccine: Provenge
8.7 Personalized Cancer Vaccines Targeting Cervical Cancer
8.8 Personalized Cancer Vaccines Application towards Glioblastoma (Brain Tumor)

9. Personalized Cancer Vaccine: Rising with New Avenues & Opportunities
9.1 Insights into the Personalized Cancer Vaccine Clinical Pipeline
9.2 Opportunities for Personalized Cancer Vaccine in the Emerging Market of the World

10. Porter’s Five Force Analysis of the Personalized Cancer Vaccine Market
10.1 Bargaining Power of Suppliers
10.2 Bargaining Power of Buyer
10.3 Threats of Substitute Products
10.4 Threat of New Entrants to the already Existing Market
10.5 Rivalry Among the Existing Competitors

11. Factors Driving  the Market of  Personalized Cancer Vaccine
11.1 Increased Demand for Personalized Cancer Vaccine Production
11.2 Increase Prevalence  of Cancer Cases in the Population Worldwide
11.3 Cancer Heterogenetic Environment
11.4 High Level of Specificity
11.5 Assistance from Government
11.6 Advancements  in Genome Sequencing Techniques Delivering better Personalized Cancer Vaccines
11.7 Robust Clinical Pipeline Under Development

12. Challenges Associated  with  Personalized Cancer Vaccine Market
12.1 Scientific & Technical Challenges in Developing a Personalized Cancer Vaccine
12.2 Commercial Challenges Surrounding Personalized Cancer Vaccines

13. Global Personalized Cancer Vaccine Market Future Outlook

14. Personalized Medicine Current Market Region Scenario
14.1 North America
14.2 Latin America
14.3 Europe
14.4 Asia-Pacific
14.4.1 Japan
14.4.2 India
14.4.3 South Korea
14.4.4 Taiwan
14.5 Middle East & Africa

15. Global Personalized Vaccine Trends

16. Competitive Landscape
16.1 Advaxis Inc.
16.2 Avax Technologies
16.3 BioNtech AG
16.4 Celldex
16.5 CureVac AG
16.6 Genetech
16.7 Genocea
16.8 Gristone Oncology
16.9 ISA Pharmaceuticals
16.10 Merck
16.11 Moderna Therapeutics
16.12 Neon Therapeutics
16.13 Personalis

List of Figures
Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
Figure 1-2: Advantages of Targeting Neo – Antigens in Cancer Vaccine Production
Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 2-3: The Sources of Pharmacological & Pharmacogenetic Variability’s
Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 3-2: Roadmap of Development of Predictive Biomarkers
Figure 4-1: Ongoing Clinical Trials on Personalized Vaccines
Figure 5-1: High Throughput Immune Assessment for Biomarker Discovery
Figure 6-1: General Overview of Personalized Cancer Vaccine Production
Figure 6-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
Figure 6-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
Figure 6-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
Figure 6-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
Figure 6-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
Figure 6-7: Gardasil – Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 6-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 6-9: Gardasil - Factory & Administrative Overheads (US$ Million), 2018
Figure 6-10: Cervarix - Factory & Administrative Overheads (US$ Million), 2018
Figure 6-11: Gardasil – Manufacturing Cost per single Dose (US$), 2018
Figure 6-12: Cervarix - Manufacturing Cost per single Dose (US$), 2018
Figure 6-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient), 2018
Figure 6-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
Figure 6-15: Gardasil & Gardasil 9 - Cost Analysis (US$), October’ 2019
Figure 7-1: Trends & Advancement in the Personalized Cancer Vaccine Segment
Figure 7-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
Figure 8-1: Alteration in CDKN2A Mechanism
Figure 8-2: Global - Melanoma & Non – Melanoma Cancer Incidence (000’), 2018
Figure 8-3: Global - Melanoma Prevalence by Region (%), 2018
Figure 8-4: Global - Lung Cancer Incidence & Deaths (Million), 2018
Figure 8-5: Global – Lung Cancer Prevalence by Region (%), 2018
Figure 8-6: Global - Breast Cancer Incidence & Deaths (Million), 2018
Figure 8-7: Global - Breast Prevalence by Region (%), 2018
Figure 8-8: Global - Colorectal Cancer Incidence & Deaths (Million), 2018
Figure 8-9: Global - Colorectal Cancer Market Size (%), 2018
Figure 8-10: Global - Leukemia Incidence (000’), 2018
Figure 8-11: Global - Leukemia Market Size (%), 2018
Figure 8-12: Global - Prostate Cancer Incidence (000’), 2018
Figure 8-13: Global - Prostate Cancer Prevalence by Region (%), 2018
Figure 8-14: Provenge - Cost Analysis (US$/Month)
Figure 8-15: Global - Cervical Cancer Incidence (000’), 2018
Figure 8-16: Global - Cervical Cancer prevalence by Region (%), 2018
Figure 9-1: Global - Oncology Market Size by Region (%), 2017
Figure 10-1: Porter’s Five Force Analysis - Overview
Figure 11-1: Driving Factors of the Personalized Cancer Vaccine Market
Figure 11-2: Global - Most Common Types of Cancer by Prevalence, 2018
Figure 11-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
Figure 11-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
Figure 12-1: Scientific Limitations in Personalized Cancer Vaccine Development
Figure 13-1: Global - Gardasil/ Gardasil 9 Sales (US$ Billion), 2018 -2026
Figure 13-2: Gardasil/ Gardasil 9 Sales - US v/s Rest of World (US$ Billion), 2018
Figure 13-3: Gardasil/ Gardasil 9 - Global Patent Insight
Figure 13-4: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2019 – 2026
Figure 14-1: US – Total Cancer Deaths, 2016 - 2018
Figure 14-2: Europe – Total Cancer Deaths, 2016 - 2018
Figure 14-3: Asia-Pacific – Total Cancer Deaths, 2018
Figure 14-4: Japan – Total Cancer Deaths, 2016 & 2018
Figure 14-5: India – Total Cancer Deaths, 2014 & 2018
Figure 14-6: South Korea – Total Cancer Deaths, 2014 - 2016
Figure 14-7: Taiwan - Total Cancer Deaths, 2017 – 2018

List of Tables
Table 8-1: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Table 8-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Advaxis Inc.
  • Alphabet
  • Avax Technologies
  • BioNtech AG
  • Celldex
  • CureVac AG
  • Genetech
  • Genocea
  • Gristone Oncology
  • ISA Pharmaceuticals
  • Kite Pharma
  • Merck
  • Moderna Therapeutics
  • Neon Therapeutics
  • Personalis
Note: Product cover images may vary from those shown
Adroll
adroll